Immupharma PLC TERM SHEET SIGNED $14 MILLION FUNDING FOR LUPUZOR (0955U)
July 27 2015 - 2:00AM
UK Regulatory
TIDMIMM
RNS Number : 0955U
Immupharma PLC
27 July 2015
27 JULY 2015
IMMUPHARMA PLC
CLINICALTRIALS.GOV REGISTRATION OF LUPUZOR(TM) PIVOTAL PHASE III
TRIAL
TERM SHEET SIGNED WITH US INVESTOR TO SECURE UP TO
$14 MILLION FUNDING FOR LUPUZOR(TM)
ImmuPharma PLC (LSE:IMM), ("ImmuPharma" or the "Company"), the
specialist drug discovery and development company is delighted to
announce that registration with the U.S. National Institutes of
Health - ClincialTrials.gov website has now gone 'live' confirming
Lupuzor's(TM) pivotal Phase III trial protocol and the current
clinical commencement and completion of the study. Further details
can be viewed at: ClincialTrials.gov.
ImmuPharma has also signed a Term Sheet with a US investor for a
proposed private placement to fund the clinical trial. The initial
instalment of funding consists of a convertible loan of
US$2,000,000 plus additional capital of up to $12,000,000, at the
Company's discretion, subject to certain criteria, over a two year
period. Further disclosure on the financial terms of this agreement
(the "Agreement") will be announced following the signature of full
agreement anticipated in the next few weeks.
Lupuzor(TM) (active name Rigerimod, also known as IPP-201101 and
P140), is ImmuPharma's lead compound for the treatment of Lupus,
(Systemic Lupus Erythematosus or "SLE"), a chronic, potentially
life-threatening autoimmune disease. Lupuzor(TM) has been granted
Fast Track status by the US FDA and approved to start Phase III
trials under a Special Protocol Assessment (SPA) due to its strong
safety and efficacy profile. Simbec-Orion, a leading full service
international Clinical Research Organisation specialising in Rare
& Orphan conditions and with previous direct experience in
Lupus trials, is conducting these trials. As part of the
collaboration agreement with Simbec-Orion, as announced in January
this year, it will invest a part of its internal invoiced costs in
ordinary shares in ImmuPharma at a price of 150p. Furthermore,
based on the French research tax credit (Crédit Impôt Recherche -
CIR), ImmuPharma France will receive a tax return in the range of
25% of the incurred costs. The combination of the current funding
mechanisms including the new US investor 'Agreement' should be
sufficient to complete this current pivotal Phase III trial of
Lupuzor(TM).
Since the commencement of work with Simbec-Orion, a number of
key and necessary steps have been undertaken including detailed
technical feasibility, site selection as well as completion of the
regulatory process in each selected country where the trials will
be conducted. Key European and US sites have now been identified
and it is anticipated that about 15 sites in the US and 20 sites in
Europe will be enrolled. Recruitment could be completed during the
summer of 2016. Patient dosing is expected to commence this
autumn.
Further updates on progress will be provided in due course.
ENDS
For further information please contact:
+ 44 (0) 20 7152
ImmuPharma plc 4080
Dimitri Dimitriou, Chief Executive
Officer
Dr Robert Zimmer, President
and Chief Scientific Officer
Lisa Baderoon, Head of Investor
Relations + 44 (0) 7721 413496
Panmure, Gordon & Co., NOMAD
& Broker +44 (0) 20 7886 2500
Hugh Morgan
Fred Walsh
Duncan Monteith
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCSEAFFMFISESW
Immupharma (LSE:IMM)
Historical Stock Chart
From Jun 2024 to Jul 2024
Immupharma (LSE:IMM)
Historical Stock Chart
From Jul 2023 to Jul 2024